Lipids Management

Seth J. Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC

Chief Scientific Officer, Flourish Research; Clinical Affiliate Professor of Cardiology, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida

Dr Baum is a graduate of Columbia University College of Physicians and Surgeons and completed training in internal medicine, cardiology, interventional cardiology, and electrophysiology.

Dr Baum has practiced preventive cardiology and clinical lipidology since 2000. He is a fellow of the American College of Cardiology, the American Heart Association, the American College of Preventive Medicine, the National Lipid Association, and the American Society for Preventive Cardiology (ASPC). Dr Baum is also a past president of the ASPC. He currently serves on both the ASPC and Family Heart Foundation Lipoprotein(a) Advisory Boards. He has published over 100 peer-reviewed papers and abstracts as well as two books. In 2013, he received Cleveland Heart Lab's Heart Award for lifelong dedication to preventive medicine. In 2019, Dr Baum received Mended Hearts' biennial Dwight Emary Harken Award. Dr Baum is the founder and chief medical officer of Excel Medical Clinical Trials, LLC, a consortium of clinicians dedicated to the safe and professional conduct of high-level scientific trials. He has served as principal investigator in over 100 clinical trials covering a broad range of disease states. Dr Baum is the chief scientific officer of Flourish Research, a leading national clinical research company.

Dr Baum is clinical affiliate professor of cardiology at Florida Atlantic University Medical School. He actively consults in clinical lipidology and cardiovascular disease prevention, and continues to offer lipoprotein apheresis for patients in southeast and central Florida.

Disclosures

Seth J. Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Altimmune; Amgen; Eli Lilly; Ionis Pharmaceuticals; Madrigal; Merck; Novartis; Regeneron
Serve(d) as a speaker or a member of a speakers bureau for: Amgen; Boehringer Ingelheim; Eli Lilly; Esperion; Regeneron
Serve(d) on the scientific advisory board for: Altimmune; Amgen; Axcella; Boehringer Ingelheim; Eli Lilly; Esperion; Madrigal; Novartis; Regeneron

Matthew J. Budoff, MD

Professor of Medicine, University of California, Los Angeles; Program Director, Department of Cardiology, Harbor UCLA Medical Center, Torrance, California

Dr Budoff has devoted much of his time over the past 25 years to advancing procedures that can help doctors identify cardiac patients early and place them on a therapeutic path to prevent heart attacks. Dr Budoff works on at least 20 active medical research trials at any given time and is a frequent lecturer on cardiology topics at symposia, congresses, and annual conferences globally. He has authored or coauthored over 800 research papers, seven books, and 45 book chapters.

Disclosures

Matthew J. Budoff, MD, has disclosed the following relevant financial relationships:
Serve(d) as a speaker or a member of a speakers bureau for: Amarin Pharma Inc.
Received research grant from: General Electric; Amarin Pharma Inc.

Seth Shay Martin, MD, MHS, FACC, FAHA, FASPC

Director, Advanced Lipid Disorders Program and Digital Health Lab, Ciccarone Center for the Prevention of Cardiovascular Disease, The Johns Hopkins Hospital; Associate Professor of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland

Disclosures

Seth Shay Martin, MD, MHS, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Amgen; AstraZeneca; NewAmsterdam; Sanofi

Pamela Bowe Morris, MD, FACC, FAHA, FASPC, FNLA

Professor of Medicine, Cardiology; Director, Seinsheimer Cardiovascular Health Program, The Medical University of South Carolina, Charleston, South Carolina

Disclosures

Pamela Bowe Morris, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Esperion

Connie B. Newman, MD, MACP, FAHA, FAMWA

Endocrinologist, Adjunct Professor of Medicine, NYU School of Medicine, New York, NY

Disclosures

Connie B. Newman, MD, has disclosed no relevant financial relationships.

Jay H. Shubrook, DO, FAAFP, FACOFP

Professor, Director of Clinical Research, Department of Primary Care, Touro College of Osteopathic Medicine, Vallejo, California; Diabetologist and Director of Diabetes Services, Solano County Family Health Services, Fairfield, California

Dr Shubrook is a board-certified family physician and fellowship-trained diabetologist. He is a professor and director of clinical research at the Touro College of Osteopathic Medicine in Vallejo, California, where he also serves as director of diabetes services. He completed his medical and fellowship training at Heritage College of Osteopathic Medicine in Athens, Ohio. He serves as an associate editor for Clinical Diabetes. His clinical and educational focus is to better prepare the primary care workforce to help manage people with diabetes and other cardiometabolic diseases.

Disclosures

Jay H. Shubrook, DO, FAAFP, FACOFP, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Abbott; AstraZeneca; Bayer; Eli Lilly; Novo Nordisk
Serve(d) on the scientific advisory board for: Nevro

Pam R. Taub, MD, FACC, FASPC

Professor of Medicine, University of California San Diego School of Medicine; Founding Director, Step Family Foundation Cardiac Rehabilitation and Wellness Center, La Jolla, California

Dr Taub is a board-certified cardiologist and founding director of the Step Family Foundation Cardiac Rehabilitation and Wellness Center at UC San Diego. Dr Taub was responsible for all aspects of creating the center, which provides a comprehensive cardiac rehabilitation program for patients with established heart disease. Her clinical practice focuses on preventive cardiology, lipidology, and women's cardiovascular health. She has extensive clinical trial experience and is active in clinical and translational research. Her research focuses on assessing the impact of behavioral, technological, and pharmacological interventions on cardiometabolic disease.

Dr Taub is a federally funded researcher with funding from the National Institutes of Health (principal investigator on R01 grant), Department of Defense, Department of Homeland Security, and American Heart Association. She is an experienced clinical trialist and serves on the executive committee for multiple international clinical trials focused on novel cardiovascular therapies.

Dr Taub is widely published (with more than 100 publications) and has authored high-impact publications in top peer-reviewed journals, including Cell Metabolism and the Journal of the American College of Cardiology.

Dr Taub holds multiple leadership positions in professional societies, serving as a fellow and board member for the American Society for Preventive Cardiology. She is a fellow and member of the American College of Cardiology Prevention of CV Disease Section Leadership Council. She also serves on the American Heart Association Council on Clinical Cardiology (Women in Cardiology Committee).

Disclosures

Pam R. Taub, MD, FACC, FASPC, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Esperion Therapeutics; Boehringer Ingelheim; Novo Nordisk; Amarin Corporation; Novartis, Medtronic, Sanofi
Serve(d) as a shareholder for: Epirium Bio